Metastatic Melanoma

NEW ORLEANS — Among Asian American and Pacific Islander subgroups, Southeast Asians had higher rates of metastatic and acral lentiginous melanoma and higher rates of ulceration, according to a presentation here.

The addition of all-trans retinoic acid to pembrolizumab conferred benefit to patients with metastatic melanoma, according to results of a phase 1b/phase 2 trial published in Clinical Cancer Research.

Certain cancer treatments and prolonged cancer survival can increase the risk of bone loss.

The FDA approved relatlimab plus nivolumab for treatment of patients aged 12 years or older with unresectable or metastatic melanoma.

Relatlimab plus nivolumab continued to demonstrate a PFS benefit compared with nivolumab alone for patients with previously untreated metastatic or unresectable melanoma, according to a study presented during an ASCO Plenary Series session.

A phase 3 trial designed to assess the addition of bempegaldesleukin to nivolumab for previously untreated unresectable or metastatic melanoma failed to meet its primary endpoint, according to the agents’ manufacturers.

Prior treatment with newer-generation therapies appeared associated with significantly lower objective response rates among patients who received tumor-infiltrating lymphocytes for metastatic melanoma, according to study findings.

Cutaneous adverse events appeared largely reversible and rarely led to therapy discontinuation among patients with metastatic melanoma treated with combination checkpoint inhibitors, according to a study in Cancer.

Patients with BRAF V600 mutation-positive metastatic melanoma who received an immune checkpoint inhibitor combination followed by targeted therapy survived longer than those who received the reverse sequence, according to study findings.

The FDA granted fast track designation to UV1 in combination with checkpoint inhibitor therapy for treatment of unresectable or metastatic melanoma.